The DOI matches its Crossref record; 50 of the 54 references it cites were found in a registry or an index.
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Open accessAbstract
Mantle cell lymphoma (MCL) carries an unfavorable prognosis and requires new treatment strategies. The associated t(11:14) translocation results in enhanced cyclin D1 expression and cyclin D1-dependent kinase activity to promote cell-cycle progression. A pharmacodynamic study of the selective CDK4/6 inhibitor PD0332991 was conducted in 17 patients with relapsed disease, using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and 3-deoxy-3[(18)F]fluorothymidine (FLT) positron emission tomography (PET) to study tumor metabolism and proliferation, respectively, in concert with pre- and on-treatment lymph node biopsies to assess retinoblastoma protein (Rb) phosphorylation and markers of proliferation and apoptosis. Substantial reductions in the summed FLT-PET maximal standard uptake value (SUV(max)), as well as in Rb phosphorylation and Ki-67 expression, occurred after 3 weeks in most patients, with significant correlations among these end points. Five patients achieved progression-free survival time of > 1 year (range, 14.9-30.1+ months), with 1 complete and 2 partial responses (18% objective response rate; 90% confidence interval, 5%-40%). These patients demonstrated > 70%, > 90%, and ≥ 87.5% reductions in summed FLT SUV(max) and expression of phospho-Rb and Ki67, respectively, parameters necessary but not sufficient for long-term disease control. The results of the present study confirm CDK4/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. This study is registered at www.clinicaltrials.gov under identifier NCT00420056.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Substantial reductions in the summed FLT-PET maximal standard uptake value (SUVmax), as well as in RB phosphorylation and Ki-67 expression, occurred after 3 weeks in most patients, with significant correlations among these end points.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [75]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, responses were not immediate but occurred after 4 to 8 cycles.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [75]
In the citing paper
“Although those patients with prolonged clinical benefit demonstrated marked first-cycle reductions in summed FLT SUVmax and in expression of phospho-RB and Ki67, such decreases also occurred in patients who did not go on to achieve prolonged benefit, suggesting population heterogeneity in responses after initial CDK4/6 inhibition.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [75]
In the citing paper
“Five of 17 heavily pretreated patients (including those who had received prior chemotherapy (bortezomib and stem cell transplant), achieved progression-free survival (PFS) of > 1 year (range, 15-30 months), with one complete and two partial responses.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
International Agency for Research on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,435
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Self-citationA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., et al. (2008) · Blood · doi:10.1182/blood-2007-06-095331 · Cited by 984
Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 914
Research works printed but not linked: 1
- O'Dwyer, 2011, Phase I/II pharmacodynamic trial of PD0332991 in patients with KRAS mutant colorectal cancer [abstract]., Ann Oncol, 22, PP01
Cited by
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
“92, 93) PD Reduced RB phosphorylation in paired tumor biopsies, along with reduced fluorothymidinePET uptake (75) Reduced RB phosphorylation and Ki67 expression in paired tumor biopsies (90) Reduced RB phosphorylation and topoisomerase IIα expression in paired tumor and skin biopsies (92)”
Self-citation
Metadata
- Authors
- Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., Neuberg, D. S., Martin, P., Millenson, M. M., Ely, S. A., Courtney, R., Shaik, N., Wilner, K. D., Randolph, S., Van den Abbeele, A. D., Chen-Kiang, S. Y., Yap, J. T., & Shapiro, G. I.
- Affiliations
- Weill Cornell Medicine (US)
- Brigham and Women's Hospital (US)
- Fox Chase Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Department of Radiology, Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY;
- Pfizer (United States) (US)
- Harvard University (US)
- Pfizer Global Research and Development, Pfizer Inc, La Jolla, CA;
- Department of Imaging, Dana-Farber Cancer Institute, Boston, MA;
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY;
- Corresponding author
- Leonard, John P.
- LaCasce, Ann S.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-05-17
- Volume
- 119
- Issue
- 20
- Pages
- 4597-4607
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2044348066
- Cited by
- 299
- References
- 54
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 11 · 2020: 20 · 2019: 17 · 2018: 17 · 2017: 31 · 2016: 23 · 2015: 38 · 2014: 46 · 2013: 29 · 2012: 13
- FWCI
- 29.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Dana-Farber/Harvard Cancer Center
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- mantle cell lymphoma, CDK4/6 inhibition, palbociclib, cyclin D1, retinoblastoma protein phosphorylation, FLT-PET, FDG-PET, Ki-67, tumor cell proliferation, relapsed lymphoma, pharmacodynamic biomarkers, progression-free survival
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Piperazines, Prognosis, Pyridines, Substrate Specificity, Treatment Outcome, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. https://app.cochat.ai/papers/10.1182/blood-2011-10-388298
- The paper
- Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., Neuberg, D. S., Martin, P., Millenson, M. M., Ely, S. A., Courtney, R., Shaik, N., Wilner, K. D., Randolph, S., Van den Abbeele, A. D., . . . Shapiro, G. I. (2012). Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. https://doi.org/10.1182/blood-2011-10-388298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.